Bioventus LLC, Pfizer deal
Bioventus acquired an exclusive, worldwide license to Pfizer's bone morphogenetic protein (BMP) portfolio and associated IP. The portfolio includes a next-generation BMP in preclinical development and rights to recombinant human BMP 2 (rhBMP-2) in undisclosed indications previously reserved to Pfizer. Bioventus also acquired an exclusive option to a BMP program for soft tissue indications. Pfizer will transfer to Bioventus all existing development work for the BMP assets and will perform early development activities relating to the next-generation BMP. Pfizer will also manufacture rhBMP-2 and supply it to Bioventus. Pfizer received an upfront payment and is eligible for milestone payments and royalties. Pfizer declined to disclose financial terms, and Bioventus could not be reached. ...